Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, LIC

Agena Bioscience Bolsters MassARRAY Insightstm Reporting Network By Adding N-of-One



SAN DIEGO, Oct. 5, 2017 /PRNewswire/ -- Agena Bioscience, a global provider of molecular genetic solutions and N-of-One Inc., a leader in molecular decision support for oncology, have teamed together to provide interpretation of cancer genomic data generated by the MassARRAY® System.

Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAYÂ(R) System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. (PRNewsFoto/Agena Bioscience) (PRNewsFoto/)

This strategic partnership supports the expansion of Agena's recently launched MassARRAY Insights reporting network, which connects the unique capabilities of the MassARRAY with the power of high quality analysis to aid in results interpretation. N-of-One's long standing expertise in clinical interpretation of molecular tests in oncology aids CLIA High Complexity Labs in rapidly delivering actionable, patient-specific treatment options that are supported by the latest scientific and clinical evidence.

"MassARRAY Insights is part of Agena Bioscience's continued effort to support our CLIA-High Complexity Certified lab customers who are tackling the challenges presented in molecular diagnostics. We are happy to partner with an industry leader like N-of-One to help bring our lab clients an important component that nicely follows the value of our test: an evidence-based, clinically actionable report," said Pete Dansky, Chief Executive Officer at Agena Bioscience.

"With technology like Agena's MassARRAY, clinicians have the ability to develop tests that provide robust data. With our data interpretation expertise, we can guide pathologists and oncologists to more precise and tailored cancer treatments than ever before. At N-of-One, we are happy to partner with Agena Bioscience, as we are aligned in tackling complex molecular data and helping to make sense of it for the clinician," said Chris Cournoyer, Chief Executive Officer at N-of-One, Inc."

Agena's MassARRAY System is intended for Research Use Only. Not for use in diagnostic procedures.

MassARRAY Insights reporting networks can be found at www.agenabio.com/services/insights

About Agena Bioscience

Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. For more information about Agena, visit www.agenabio.com.

About N-of-One
N-of-One is a leader in identifying patient-specific therapeutic options for precision medicine in oncology by leveraging its proprietary knowledgebase and its team of oncologists and Ph.D. scientists to integrate molecular data from multiple tests. Using N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One's solutions have provided therapeutic options, including clinical trials, for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world. For more information, please visit www.n-of-one.com or call +1 617-202-9808.

 

SOURCE Agena Bioscience


These press releases may also interest you

at 09:45
NEW YORK, Oct. 21, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating Sunshine Bancorp, Inc....

at 09:30
LOS ANGELES, Oct. 21, 2017 /PRNewswire-iReach/ -- Onlinecarinsuranceinfo.com has released a new blog post explaining the advantages of having high deductibles with an auto insurance plan. A collision auto insurance works based on premiums and...

at 09:00
VANCOUVER, Oct. 20, 2017 /CNW/ - The Honourable Ginette Petitpas Taylor, Federal Minister of Health, will announce additional support for the BC Centre of Excellence for Women's Health through Health Canada's Substance Use and Addictions Program to...

at 08:55
LONDON, Oct. 21, 2017 /PRNewswire/ -- DOVU's token sale has ended. The company collected a total of 20,000 Ether (ETH), with a current value of $6.2 million. This puts the project in a strong position to move forwards to build and market its core...

at 08:00
LOS ANGELES, Oct. 21, 2017 /PRNewswire-iReach/ -- Auto-car-insurance4.info has released a new blog post explaining why safety devices can improve auto insurance premiums. Drivers should focus on the safety of their cars. A family vehicle with a...

at 06:00
City ranks high in Toronto Global bid VAUGHAN, ON, Oct. 21, 2017 /CNW/ - The City of Vaughan is one of Canada's fastest-growing municipalities, brimming with talent and urban amenities that can provide world-class companies like Amazon with...




News published on 5 october 2017 at 09:17 and distributed by: